================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Mark One)
|X| Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended September 30, 1996.
OR
|_| Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the Transition period ______________ to _____________.
Commission File Number: 0-21209
ADVANCED HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 13-3893841
(State or other jurisdiction of (IRS Employer
incorporation or organization Identification No.)
555 White Plains Road
Tarrytown, New York 10591
(Address of principal executive offices, including zip code)
(914) 524-4200
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes |_| No |X|
As of November 18, 1996, there were 7,145,267 shares outstanding of the
registrant's Common Stock, $.01 par value.
================================================================================
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
November 19, 1996 ADVANCED HEALTH CORPORATION
By: /s/ Jonathan Edelson
---------------------------
Jonathan Edelson, M.D.
Chairman of the Board and
Chief Executive Officer
(Principal Executive Officer)
By: /s/ Alan B. Masarek
---------------------------
Alan B. Masarek
Chief Operating Officer and
Chief Financial Officer
(Principal Financial and Accounting Officer)
(2)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR SECTION 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 1996.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> SEP-30-1996
<CASH> 59
<SECURITIES> 0
<RECEIVABLES> 4,684
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 5,398
<PP&E> 2,204
<DEPRECIATION> 632
<TOTAL-ASSETS> 9,001
<CURRENT-LIABILITIES> 8,980
<BONDS> 170
0
0
<COMMON> 45
<OTHER-SE> (194)
<TOTAL-LIABILITY-AND-EQUITY> 9,001
<SALES> 12,172
<TOTAL-REVENUES> 12,172
<CGS> 5,964
<TOTAL-COSTS> 5,964
<OTHER-EXPENSES> 8,929 <F1>
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 151
<INCOME-PRETAX> (2,870)
<INCOME-TAX> 0
<INCOME-CONTINUING> (2,870)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,870)
<EPS-PRIMARY> (.57)
<EPS-DILUTED> (.57)
<FN>
<F1> INCLUDES $2,843 OF R&D EXPENSES
</FN>
</TABLE>
